BASEL, Switzerland, Nov. 03, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for ...
A study led by CIC bioGUNE delves into the complexity of the most aggressive form of prostate cancer
Cancer cannot be understood as a single, uniform disease. The more we delve into studying each type of tumor, the more we recognize the need to subclassify the disease. This concept has led to what we ...
BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for ...
CIC bioGUNE leads a study showing that multi-omic data can identify silent and stable risk profiles in healthy individuals The study, conducted using local cohorts from the Basque Country, ...
VectivBio Holding AG (VectivBio), a clinical-stage biopharmaceutical company, announced the completion of enrollment of the Colon-in-Continuity (CIC) cohort for the company’s phase 3 STARS (STudy of ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced new insights that highlighted the frustrations many patients with chronic idiopathic constipation (CIC) feel with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results